Growing Demand For At-Home Testing Is Fueling Growth Of The Fecal Calprotectin Test Market
The global fecal calprotectin test market is estimated to be
valued at US$ 140.6 Mn in 2023 and
is expected to exhibit a CAGR of 12.3%
over the forecast period 2023-2030, as highlighted in a new report published by
Coherent Market Insights.
Market Overview:
Fecal calprotectin tests helps in diagnosis of inflammatory bowel disease such
as ulcerative colitis and Crohn's disease. The advantages of fecal calprotectin
tests are that it is non-invasive, effective and accurate for diagnosing
gastrointestinal inflammation and damage.
Market key trends:
One of the key trends in the fecal calprotectin tests market is growing
preference for point-of-care and at-home testing. At-home collection and
mail-in testing provides convenience to patients. At-home fecal calprotectin
tests allow for more frequent non-invasive monitoring of gastrointestinal
diseases and their treatments compared to physician office visits. This has
supported increased testing volumes and boosted the market growth.
Segment
Analysis
The global fecal calprotectin test market is segmented into technology, test
type, sample type, end use and region. Based on technology, the market is
categorized into enzyme-linked immunosorbent assay (ELISA), calprotectin rapid
tests and others. The ELISA segment dominates the market as it is considered
the gold standard for detection of fecal calprotectin levels. Based on test
type, the market is divided into quantitative and qualitative tests.
Quantitative tests hold a larger share as they provide accurate calprotectin
level measurement. By sample type, the market covers stool and blood samples,
with stool samples being used more widely due to ease of collection. On the
basis of end use, the market covers hospitals & clinics, diagnostic
laboratories and research & academic institutes. Hospitals & clinics
account for the largest share due to high patient footfall.
Key Takeaways
The Global
Fecal Calprotectin Test Market Size is expected to witness high growth,
exhibiting a CAGR of 12.3% over the
forecast period, due to increasing incidence of gastrointestinal disorders.
Regional analysis - North America dominates the global market due to rising
prevalence of inflammatory bowel disease. Europe holds the second largest share
owing to increasing awareness about fecal calprotectin tests. Asia Pacific
exhibits the fastest growth due to growing healthcare infrastructure and
healthcare expenditure in countries such as China and India.
Key players - Key players operating in the fecal calprotectin test market are
Thermo Fisher Scientific Inc., Bio-Rad Laboratories, Inc., F. Hoffmann-La Roche
Ltd., Becton, Dickinson and Company, Abbexa Limited, Bioserv Diagnostics Gmbh,
Epitope Diagnostics, Inc., LifeSpan BioSciences, Inc., RayBiotech, Inc., ALPCO.
Thermo Fisher Scientific and F. Hoffmann-La Roche Ltd. hold a major share of
the market due to their diversified product portfolios.
Read
More: https://www.ukwebwire.com/fecal-calprotectin-test-market-size-share-and-growth-forecast-2023-2023/
Comments
Post a Comment